Document is current
Any future updates will be listed below
-
Authors
Xu, Nannan
Zhu, Yemin
Han, Yichao https://orcid.org/0000-0002-9691-3028
Liu, Qi
Tong, Lingfeng
Li, Yakui
Chen, Zhangbing
Shao, Sijia
He, Wenrui
Li, Mingrui https://orcid.org/0000-0003-1217-6567
Wang, Yi
Qiang, Siyuan
Chai, Peiwei https://orcid.org/0000-0002-9135-0940
Du, Peng https://orcid.org/0000-0001-9355-0789
Zhao, Wenyi
Wu, Lifang https://orcid.org/0000-0001-8730-9868
Zhang, Ping
He, Jianli https://orcid.org/0000-0002-7997-6959
Li, Hecheng https://orcid.org/0000-0001-8069-6033
Cheng, Jinke https://orcid.org/0000-0002-4344-5363
Jia, Renbing https://orcid.org/0000-0001-6642-7451
Li, Bin https://orcid.org/0000-0002-7640-8884
Lu, Ying https://orcid.org/0000-0002-3545-1026
Tong, Xuemei https://orcid.org/0000-0002-2127-2019
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 17 June 2025
First Online: 22 August 2025
Competing interests
: B.L. is a co-founder of Biotheus and chairman of its scientific advisory board. X.T. has a patent related to the MondoA–TXNIP therapy in cancers. The remaining authors declare no competing interests.
